Welcome to our dedicated page for Nevro SEC filings (Ticker: NVRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating spinal cord stimulation metrics, FDA milestones, and reimbursement disclosures in Nevro’s SEC paperwork can feel like surgery without anesthesia. The company’s 10 kHz therapy, AI-enabled HFX AdaptivAI and global device rollouts mean its reports are packed with clinical jargon and regulatory nuance. Stock Titan decodes these complexities so you don’t have to—Nevro SEC filings explained simply.
Open a Nevro quarterly earnings report 10-Q filing and our AI surfaces implant volume trends, gross-margin shifts, and geographic sales in seconds. Drill into a Nevro annual report 10-K simplified to see R&D spend on next-generation neuromodulation and reimbursement risk factors without wading through 200+ pages. Need immediate alerts? Nevro Form 4 insider transactions real-time show when executives adjust their positions, while a Nevro 8-K material events explained flags new FDA approvals or clinical-trial readouts the moment they post.
Whether you’re tracking Nevro insider trading Form 4 transactions, comparing segment performance through Nevro earnings report filing analysis, or reviewing a Nevro proxy statement executive compensation before voting season, our platform delivers:
- AI-powered summaries that translate medical and financial terminology
- Real-time feeds from EDGAR across every form type
- Quick links to Nevro executive stock transactions Form 4 and other granular data points
Join analysts, portfolio managers, and med-tech specialists already understanding Nevro SEC documents with AI—because precision matters when high-frequency therapy meets high-stakes investment decisions.
Nevro Corp. was the subject of a Schedule 13G/A filed by Beryl Capital entities and David A. Witkin reporting that none of the reporting persons beneficially own shares of Nevro common stock. The filing lists Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin as reporting persons, states their organizational relationships, and includes a disclaimer that they do not claim beneficial ownership except for any pecuniary interest. The statement shows 0 shares beneficially owned and 0% of the class, with all voting and dispositive powers reported as zero, indicating no current economic or voting stake disclosed in this filing.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly reported beneficial ownership of 1,172 shares of Nevro Corp. common stock, representing 0.0% of the class. The filing shows shared voting power of 905 shares and shared dispositive power of 1,172 shares, with no sole voting or dispositive power recorded.
The Schedule 13G/A states these holdings are reported as held in the ordinary course of business and not for the purpose of influencing control. The filing also discloses that Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc., and the parties executed a joint filing agreement documenting the joint submission.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
